{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"90"},{"groupId":"OG001","value":"276"},{"groupId":"OG002","value":"19"}],"title":"MEN1"},{"measurements":[{"groupId":"OG000","value":"61"},{"groupId":"OG001","value":"116"},{"groupId":"OG002","value":"0"}],"title":"Other familial"},{"measurements":[{"groupId":"OG000","value":"456"},{"groupId":"OG001","value":"419"},{"groupId":"OG002","value":"0"}],"title":"Sporadic"},{"measurements":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"89"},{"groupId":"OG002","value":"0"}],"title":"Unknown - insufficient information"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"634"},{"groupId":"OG001","value":"900"},{"groupId":"OG002","value":"19"}],"units":"Participants"}],"description":"The purpose of this study is to understand the causes of primary hyperparathyroidism, to evaluate and improve methods for diagnosis and treatment, and to provide insight into the mechanisms of normal parathyroid function. Hereditary causes of primary hyperparathyroidism will be characterized. Patients were categorized as follows:\n\n1. MEN1: Diagnosed by demonstration of a germline variant in MEN1 gene or one of the following: a) two of three primary MEN1 manifestations b) one primary MEN1 manifestation with a family member with MEN1.\n2. Other familial: Non-MEN1 patients who had a positive family history of hyperparathyroidism suspicious for underlying germline predisposition syndrome.\n3. Sporadic: Patients who did not have a positive family history of hyperparathyroidism.\n4. Unknown: No data to help categorize the patients in any of the above categories.","groups":[{"description":"Patients with confirmed or suspected primary hyperparathyroidism or complications who are missing age and other baseline data because of changes in data management system","id":"OG000","title":"Primary Hyperparathyroidism - Incomplete Data"},{"description":"Patients with confirmed or suspected primary hyperparathyroidism or complications","id":"OG001","title":"Primary Hyperparathyroidism"},{"description":"Patients scanned using imaging agents 68GALLIUM-DOTATATE and 18F-DOPA\n\n68Ga-Dotatate: 68Ga-Dotatate PET/CT will be administered prior to a PET/CT scan to detect known and occult primary and metastatic bronchial, gastrointestinal and pancreatic neuroendocrine tumors.\n\n18F-DOPA: 18F-DOPA PET/CT will be administered prior to a whole-body scan to detect known and occult primary and metastatic bronchial, gastrointestinal and pancreatic neuroendocrine tumors.","id":"OG002","title":"DOTATATE and F-DOPA"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"First year","title":"Type of Hyperparathyroidism","type":"PRIMARY","unitOfMeasure":"Participants"}